PTGS2 and neoplasm: Nuclear medical in vivo preclinical model systems applying target-selective radiolabelled compounds may aid to further understand the molecular pathways of COX2/PGE2 that would attribute to the identification of well-suited diagnostic and anti-tumor biomarkers.